Breaking ICE Presence at Airports Raises Concerns Among Airline Staff U.S. Treasury to Double Bond Buybacks Amid Rising Yields President Trump Showcases White House Construction and Renovation Projects Rory McIlroy Questions Value of LIV Golf Stars Amidst League Uncertainty WNBA Star Nneka Ogwumike Announces Retirement, Plans New International Basketball Venture

Wednesday August 19, 2026

Reporter

Acurx Pharmaceuticals, Inc.

5Articles Published

5Communities Covered

Published Articles

Press Release

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company’s Brand Name for Ibezapolstat

Aug 17

Press Release

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update

Aug 14

Press Release

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Aug 12

Press Release

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx’s DNA Polymerase IIIC Inhibitor Antibiotics

Aug 10

Press Release

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Aug 3